287 related articles for article (PubMed ID: 11098314)
1. Experiences at a large teaching hospital with levofloxacin for the treatment of community-acquired pneumonia.
Clark LC; Davis CW
Am J Health Syst Pharm; 2000 Nov; 57 Suppl 3():S10-3. PubMed ID: 11098314
[TBL] [Abstract][Full Text] [Related]
2. Approaches to drug therapy, formulary, and pathway management in a large community hospital.
Halley HJ
Am J Health Syst Pharm; 2000 Nov; 57 Suppl 3():S17-21. PubMed ID: 11098316
[TBL] [Abstract][Full Text] [Related]
3. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of length of stay, total costs, and treatment success between intravenous moxifloxacin 400 mg and levofloxacin 750 mg among hospitalized patients with community-acquired pneumonia.
Friedman H; Song X; Crespi S; Navaratnam P
Value Health; 2009; 12(8):1135-43. PubMed ID: 19695010
[TBL] [Abstract][Full Text] [Related]
5. Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: a US-based study.
Frei CR; Jaso TC; Mortensen EM; Restrepo MI; Raut MK; Oramasionwu CU; Ruiz AD; Makos BR; Ruiz JL; Attridge RT; Mody SH; Fisher A; Schein JR
Curr Med Res Opin; 2009 Apr; 25(4):859-68. PubMed ID: 19231913
[TBL] [Abstract][Full Text] [Related]
6. A cost-minimization analysis comparing azithromycin-based and levofloxacin-based protocols for the treatment of patients hospitalized with community-acquired pneumonia: results from the CAP-IN trial.
Samsa GP; Matchar DB; Harnett J; Wilson J
Chest; 2005 Nov; 128(5):3246-54. PubMed ID: 16304269
[TBL] [Abstract][Full Text] [Related]
7. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
8. Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.
Signorovitch JE; Sheng Duh M; Sengupta A; Gu A; Grant R; Raut M; Mody SH; Schein J; Fisher AC; Ng D
Curr Med Res Opin; 2010 Feb; 26(2):355-63. PubMed ID: 19995325
[TBL] [Abstract][Full Text] [Related]
9. Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patients.
Izadi M; Dadsetan B; Najafi Z; Jafari S; Mazaheri E; Dadras O; Heidari H; SeyedAlinaghi S; Voltarelli F
Recent Pat Antiinfect Drug Discov; 2018; 13(3):228-239. PubMed ID: 30360748
[TBL] [Abstract][Full Text] [Related]
10. A controlled trial of a critical pathway for treating community-acquired pneumonia: the CAPITAL study. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin.
Feagan BG
Pharmacotherapy; 2001 Jul; 21(7 Pt 2):89S-94S. PubMed ID: 11446524
[TBL] [Abstract][Full Text] [Related]
11. Intravenous-to-oral transition therapy in community-acquired pneumonia: the INOVA Health System experience.
Milkovich G
Pharmacotherapy; 2001 Jul; 21(7 Pt 2):83S-88S. PubMed ID: 11446523
[TBL] [Abstract][Full Text] [Related]
12. [Oral levofloxacin versus intravenous ceftriaxone and amoxicillin/clavulanic acid in the treatment of community-acquired pneumonia that requires hospitalization].
Kalbermatter V; Bagilet D; Diab M; Javkin E
Med Clin (Barc); 2000 Nov; 115(15):561-3. PubMed ID: 11141388
[TBL] [Abstract][Full Text] [Related]
13. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
Lloyd A; Holman A; Evers T
Curr Med Res Opin; 2008 May; 24(5):1279-84. PubMed ID: 18358083
[TBL] [Abstract][Full Text] [Related]
14. An economic and outcomes assessment of first-line monotherapy in the treatment of community-acquired pneumonia within managed care.
Skrepnek GH; Armstrong EP; Malone DC; Ramachandran S
Curr Med Res Opin; 2005 Feb; 21(2):261-70. PubMed ID: 15801997
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of full-course oral levofloxacin in severe community-acquired pneumonia.
Wasserfallen JB; Erard V; Cometta A; Calandra T; Lamy O
Eur Respir J; 2004 Oct; 24(4):644-8. PubMed ID: 15459145
[TBL] [Abstract][Full Text] [Related]
16. Full-course oral levofloxacin for treatment of hospitalized patients with community-acquired pneumonia.
Erard V; Lamy O; Bochud PY; Bille J; Cometta A; Calandra T
Eur J Clin Microbiol Infect Dis; 2004 Feb; 23(2):82-8. PubMed ID: 14727149
[TBL] [Abstract][Full Text] [Related]
17. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin.
Palmer CS; Zhan C; Elixhauser A; Halpern MT; Rance L; Feagan BG; Marrie TJ
Clin Ther; 2000 Feb; 22(2):250-64. PubMed ID: 10743984
[TBL] [Abstract][Full Text] [Related]
18. Impact of atypical coverage for patients with community-acquired pneumonia managed on the medical ward: results from the United States Community-Acquired Pneumonia Project.
Frei CR; Koeller JM; Burgess DS; Talbert RL; Johnsrud MT
Pharmacotherapy; 2003 Sep; 23(9):1167-74. PubMed ID: 14524648
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.
Llop CJ; Tuttle E; Tillotson GS; LaPlante K; File TM
Hosp Pract (1995); 2017 Feb; 45(1):1-8. PubMed ID: 28064542
[TBL] [Abstract][Full Text] [Related]
20. Levofloxacin versus ceftriaxone plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization.
Querol-Ribelles JM; Tenías JM; Querol-Borrás JM; Labrador T; Nieto A; González-Granda D; Martínez I
Int J Antimicrob Agents; 2005 Jan; 25(1):75-83. PubMed ID: 15620830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
